Your browser doesn't support javascript.
loading
Effects of BCG vaccination on donor unrestricted T cells in two prospective cohort studies.
Gela, Anele; Murphy, Melissa; Rodo, Miguel; Hadley, Kate; Hanekom, Willem A; Boom, W Henry; Johnson, John L; Hoft, Daniel F; Joosten, Simone A; Ottenhoff, Tom H M; Suliman, Sara; Moody, D Branch; Lewinsohn, David M; Hatherill, Mark; Seshadri, Chetan; Nemes, Elisa; Scriba, Thomas J; Briel, Libby; Veldtsman, Hellen; Khomba, Nondumiso; Pienaar, Bernadette; Africa, Hadn; Steyn, Marcia.
Afiliação
  • Gela A; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Murphy M; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Rodo M; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa; Department of Statistical Sciences, University of Cape Town, Cape Town, South Africa.
  • Hadley K; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Hanekom WA; Africa Health Research Institute, KwaZulu-Natal, South Africa.
  • Boom WH; Tuberculosis Research Unit, Department of Medicine, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
  • Johnson JL; Tuberculosis Research Unit, Department of Medicine, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
  • Hoft DF; Division of Infectious Diseases, Allergy & Immunology, Edward A. Doisy Research Center, Saint Louis University School of Medicine, St. Louis, MO, USA.
  • Joosten SA; Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.
  • Ottenhoff THM; Department of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.
  • Suliman S; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa; Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medi
  • Moody DB; Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Lewinsohn DM; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Oregon Health & Science University, Portland, OR, USA.
  • Hatherill M; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Seshadri C; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA.
  • Nemes E; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Scriba TJ; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa. Electronic address: thomas.scriba@uct.ac.za.
  • Briel L; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Veldtsman H; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Khomba N; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Pienaar B; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Africa H; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Steyn M; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
EBioMedicine ; 76: 103839, 2022 Feb.
Article em En | MEDLINE | ID: mdl-35149285
ABSTRACT

BACKGROUND:

Non-protein antigen classes can be presented to T cells by near-monomorphic antigen-presenting molecules such as CD1, MR1, and butyrophilin 3A1. Such T cells, referred to as donor unrestricted T (DURT) cells, typically express stereotypic T cell receptors. The near-unrestricted nature of DURT cell antigen recognition is of particular interest for vaccine development, and we sought to define the roles of DURT cells, including MR1-restricted MAIT cells, CD1b-restricted glucose monomycolate (GMM)-specific T cells, CD1d-restricted NKT cells, and γδ T cells, in vaccination against Mycobacterium tuberculosis.

METHODS:

We compared and characterized DURT cells following primary bacille Calmette-Guerin (BCG) vaccination in a cohort of vaccinated and unvaccinated infants, as well as before and after BCG-revaccination in adults.

FINDINGS:

BCG (re)vaccination did not modulate peripheral blood frequencies, T cell activation or memory profiles of MAIT cells, CD1b-restricted GMM-specific and germline-encoded mycolyl-reactive (GEM) cells or CD1d-restricted NKT cells. By contrast, primary BCG vaccination was associated with increased frequencies of γδ T cells as well as a novel subset of CD26+CD161+TRAV1-2- IFN-γ-expressing CD4+ T cells in infants.

INTERPRETATION:

Our findings, that most DURT cell populations were not modulated by BCG, do not preclude a role of BCG in modulating other qualitative aspects of DURT cells. More studies are required to understand the full potential of DURT cells in new TB vaccine strategies.

FUNDING:

Aeras, the National Institutes of Health, and the Bill and Melinda Gates Foundation.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 3_ND / 4_TD Base de dados: MEDLINE Assunto principal: Células T Invariantes Associadas à Mucosa / Mycobacterium tuberculosis Tipo de estudo: Etiology_studies / Observational_studies / Qualitative_research / Risk_factors_studies Limite: Adult / Humans / Infant Idioma: En Revista: EBioMedicine Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 3_ND / 4_TD Base de dados: MEDLINE Assunto principal: Células T Invariantes Associadas à Mucosa / Mycobacterium tuberculosis Tipo de estudo: Etiology_studies / Observational_studies / Qualitative_research / Risk_factors_studies Limite: Adult / Humans / Infant Idioma: En Revista: EBioMedicine Ano de publicação: 2022 Tipo de documento: Article